Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Blue Owl Technology Finance Corp. reported Q3 2026 financial results with GAAP net investment income of $0.34 per share and a net asset value of $14.32 per share. The company declared a total dividend of $0.32 per share for the quarter and repurchased $35 million of common stock. Management noted strong credit quality and a 10.3% annualized return on net income.
Term
Q3 2026
“We are very pleased with OBDC's results this quarter, resulting in a 10.3% annualized return on net income. Earnings continued to comfortably cover the base dividend and NAV increased 40 basis points. Our borrowers have sustained year-over-year growth and credit quality remained strong, with no new issuers added to non-accrual.”
Craig W. Packer, Chief Executive Officer
“Looking ahead, we are well positioned to benefit from improved market economics as investments originated at wider spreads begin to fund, while higher base rates could provide an additional tailwind as our floating-rate loans reset.”
Mineralys Therapeutics reported Q3 2026 financial results and provided a corporate update regarding its lead candidate, lorundrostat, which has a PDUFA target date of December 22, 2026. The company also announced the resignation of board member Derek DiRocco, Ph.D., effective December 31, 2026.
“With approximately 20 million adults in the U.S. living with uncontrolled or resistant hypertension, despite treatment, there is a significant need for new treatment options. As we approach the December 22nd PDUFA target date for lorundrostat, our focus is on completing our launch preparations so that we are ready to reach patients quickly, pending approval.”
Jon Congleton, Chief Executive Officer of Mineralys
“We continue to receive positive feedback from providers, payers and people living with hypertension, and we look forward to the potential to bring lorundrostat to millions of patients in need.”
Jon Congleton, Chief Executive Officer of Mineralys
Kailera Therapeutics reported Q3 2026 financial results, ending the period with $847.4 million in cash and equivalents to support operations into mid-2028. The company highlighted significant clinical progress, including the full enrollment of its KaiNETIC Phase 3 program for injectable ribupatide and plans to initiate a Phase 3 program for oral ribupatide in 1H 2027.
Term
Q3 2026
“Kailera was built to bring new medicines to people living with obesity, and our strong execution this quarter reflects that commitment. All four of our product candidates are on track to deliver important clinical milestones in 2027, including the initiation of our Phase 3 trial for ribupatide oral and the data readout from the ribupatide injection high-dose Phase 2b trial. With the ribupatide franchise’s category-leading potential at the core of a diversified portfolio, and a balance sheet that supports multiple value-creating inflection points into mid-2028, I am proud of our team and energized by what we aim to deliver for people living with obesity.”
Ron Renaud, President and Chief Executive Officer of Kailera
CNB Financial Corp reported net interest income of $226.0 million for the nine months ended September 30, 2026, a significant increase from $167.8 million in the prior year period. Total assets remained stable at approximately $8.4 billion, while the company saw growth in its loan portfolio and wealth management fees.
Design Therapeutics reported third quarter 2026 financial results, posting a net loss of $20.3 million. The company ended the period with $208.6 million in cash and securities, which it expects will provide a strong financial runway for its clinical-stage GeneTAC programs. Key upcoming milestones include a registrational plan update for DT-216P2 in Q4 2026 and 12-week clinical data in Q1 2027.
“We remain focused on evaluating DT-216P2 over longer treatment durations and preparing for the next stage of clinical development in Friedreich ataxia. In DM1, our Phase 1 trial of DT-818 is evaluating an approach designed to selectively reduce transcription of the mutant DMPK allele, targeting the source of toxic RNA. Clinical readouts expected in 2027 will help guide these programs as we pursue our vision for the GeneTAC® platform: to address the underlying causes of serious genetic diseases and deliver meaningful benefits for patients.”
Pratik Shah, Ph.D., chairperson and chief executive officer of Design Therapeutics
Vaxcyte reported third quarter 2026 financial results and provided a business update, highlighting positive topline Phase 3 data for its VAX-31 adult pneumococcal vaccine candidate. The company strengthened its balance sheet with $1.1 billion in net proceeds from October equity and debt offerings, resulting in a pro forma cash position of approximately $3.4 billion. Vaxcyte remains on track for a planned BLA submission for VAX-31 in the first half of 2028.
Term
Q3 2026
“The positive topline results from OPUS-1 represent a significant milestone for Vaxcyte and our broad-spectrum pneumococcal conjugate vaccine (PCV) franchise. VAX-31 met all prespecified primary endpoints in this pivotal Phase 3 trial, which inaugurated a more stringent noninferiority standard, and we believe the results further support its potential best-in-class profile.”
Grant Pickering, Chief Executive Officer and Co-Founder of Vaxcyte
“Following our positive OPUS-1 results, we completed concurrent equity and convertible senior notes offerings, raising approximately $1.1 billion in net proceeds, to further strengthen our balance sheet and extend our cash runway. With approximately $3.4 billion in pro forma cash, cash equivalents and investments as of September 30, 2026, we are well positioned to support the potential U.S. commercial launch of VAX-31 for adults and advance our other key initiatives.”
Andrew Guggenhime, President and Chief Financial Officer of Vaxcyte
Remitly Global, Inc. reported significant growth for the nine months ended September 30, 2026, with revenue increasing to $1.46 billion from $1.19 billion in the prior year. The company achieved a substantial net income of $322.5 million, largely bolstered by a $136.0 million income tax benefit, compared to $26.7 million in the same period of 2025.
Root, Inc. reported total assets of $1.67 billion as of September 30, 2026, with a cash and cash equivalents balance of $596.3 million. The company maintains a dual-class stock structure with 13.4 million Class A and 1.8 million Class B shares outstanding as of late October 2026. Management's forward-looking statements emphasize a focus on embedded insurance partnerships, telematics data efficiency, and achieving long-term profitability.
agilon health, inc. reported a significant financial turnaround for the nine months ended September 30, 2026, achieving a net income of $101.8 million compared to a net loss of $202.5 million in the prior year period. This improvement was driven by a reduction in medical services expenses and a $19.0 million gain from discontinued operations.
Haverty Furniture Companies reported a net income of $6.3 million for the third quarter of 2026, an increase from $4.7 million in the prior year period. Net sales grew to $203.2 million, driven by improved gross margins and operational efficiencies despite higher selling, general, and administrative expenses.
Fastly reported record third-quarter revenue of $190.2 million, representing 20% year-over-year growth, driven by strong adoption of security and network services. The company achieved record gross margins and generated positive free cash flow of $25.2 million. CEO Kip Compton highlighted the results as a reflection of customers deepening their use of the platform for AI scale and critical business outcomes.
Term
Q3 2026
“Our record third quarter results reflect strong execution as customers continued to adopt more of our products and deepen their use of our platform. Delivering record revenue and free cash flow demonstrates our value proposition as we help customers achieve critical business outcomes and build for AI scale.”
Veracyte reported Q3 2026 financial results with total revenue growing 15% year-over-year to $151.8 million, driven by strong performance in its Afirma and Decipher Prostate tests. The company also announced that its Board of Directors authorized a new $100 million share repurchase program to be executed over a one-year period.
“We delivered solid third quarter results supported by strong profitability and cash generation. Afirma outperformed, while Decipher Prostate volume was below our expectations. We remain confident in the long-term outlook of our business and expect a number of evidence-based catalysts to support growth in our core franchises while also advancing our breast and bladder strategies. As we execute on these opportunities, our differentiated financial profile enables us to continue investing in the business to drive long-term growth.”
Rapid7 reported third quarter 2026 financial results with total revenue of $212.4 million, a 2.5% year-over-year decrease. The company achieved GAAP net income of $3.5 million and non-GAAP net income of $47.4 million, while maintaining an annualized recurring revenue (ARR) of $819.7 million.
Term
Q3 2026
“Last quarter, we took decisive action to focus resources and energy on our core business. This quarter, we delivered on some of our early goals in this multi-quarter journey. The company is operating with greater discipline, our core business is becoming more stable, and our cash generation outlook for the year remains on track. That is real progress, but one quarter of stability is just a start. Turning this execution into durable growth is the work ahead of us.”
Wael Mohamed, CEO of Rapid7
“Discipline creates capacity, and strategy decides where it goes. We are putting that capacity behind our core and an AI-first service model where our platform, Rapid7 Intelligence, AI agents, and experienced security experts work as one system, taking customers beyond detection and response to resolution.”
Figma reported Q3 2026 revenue of $391.4 million, up 43% year-over-year, driven by strong seat expansion and AI credit consumption. The company achieved a non-GAAP operating income of $47.0 million and raised its full-year outlook based on momentum in AI-powered design tools and cost efficiencies.
Term
Q3 2026
“As code becomes a commodity, value is moving up the stack to design—and our Q3 results reflect that. We're building the full-stack canvas for visual-first development: one that's built for collaboration, increasingly powered by our first-party model and native to the way teams design and build with AI. This is Figma's opportunity and what we believe will fuel our next phase of growth.”
Dylan Field, Figma’s CEO and co-founder
“Q3 revenue grew 43% year-over-year, coming in well ahead of our prior guidance as customers continued to expand seats and invest more deeply in Figma. We’re seeing customers move from trying AI to making larger commitments, and the Figma agent is expanding how they use credits across our platform. That momentum, alongside improvements in AI cost efficiency, gives us confidence to raise our full-year revenue and non-GAAP operating income outlook while continuing to invest in our AI capabilities.”
Nuvation Bio Inc. reported financial results for the third quarter of 2026, highlighting continued progress in its clinical oncology programs. The company maintained a robust cash position to support operations through 2028, while reporting a net loss driven by ongoing research and development expenses.
AppLovin reported record Q3 2026 financial results with revenue growing 55% year-over-year to $2.18 billion and net income increasing 72% to $1.44 billion. The company also announced that its board of directors approved a $3.2 billion increase to its share repurchase authorization, bringing the total current capacity to $3.6 billion.
Barrett Business Services reported Q3 2026 revenue of $334.1 million, up 5% year-over-year, and gross billings of $2.40 billion. Net income for the quarter was $16.8 million, or $0.69 per diluted share, as the company navigated soft client hiring trends. The company also declared a quarterly dividend of $0.08 per share and repurchased $9.0 million of common stock during the quarter.
Term
Q3 2026
“BBSI delivered third quarter results in line with our expectations, reflecting continued execution against our controllable growth initiatives and disciplined operational management.”
Gary Kramer, President and CEO
“Although client hiring trends remain soft, we are encouraged by improving conditions in the workers’ compensation market and our continued ability to secure rate increases.”
TKO Group Holdings reported Q3 2026 revenue of $1.36 billion and net income of $277.9 million, driven by strong performance at UFC and the IMG segment. The company raised its full-year 2026 revenue guidance to a range of $5.79 billion to $5.83 billion and announced plans for additional share repurchases.
Term
Q3 2026
“Our third quarter performance reflects the secular tailwinds powering live events and experiences around the world, and TKO’s assets sit front and center of that premium ecosystem. As we close out what we’ve called our year of execution, our decision to raise full-year guidance for the second time this year is the clearest expression of our conviction across the entire portfolio. Our business is durable and our fundamentals are solid, with the vast majority of our existing revenues locked in for the next five to seven years. Macro trends are firmly in our favor, every facet of sports consumption is pointing north, and we see substantial runway ahead.”
Arcus Biosciences reported third-quarter 2026 financial results, ending the period with $694 million in cash and marketable securities. The company highlighted clinical progress for its HIF-2α inhibitor, casdatifan, with Phase 3 enrollment for the PEAK-1 study in kidney cancer expected to complete within three months.
“In October, we showed for the first time that robust and durable HIF-2α inhibition from casdatifan can address the needs of patients at every line of kidney cancer therapy: rapid and sustained disease control in the first line, durable benefit and potential survival advantage in the second line, even after a prior TKI-inclusive therapy, and nearly three years of median overall survival in late-line patients who had exhausted multiple therapies.”
Terry Rosen, Ph.D., chief executive officer of Arcus
“With PEAK-1 enrollment nearing completion and PEAK-20 set to begin by year-end, we are building the registrational evidence to make casdatifan the backbone of treatment across the continuum of care for clear cell renal cell carcinoma.”
Terry Rosen, Ph.D., chief executive officer of Arcus
Crown Castle reported Q3 2026 financial results and updated its full-year 2026 outlook, raising its site rental revenue and net income guidance midpoints. The filing also reclassifies $157 million in cash outflows from investing to operating activities to align with its Form 10-Q reporting.
Term
Q3 2026
“In the third quarter, we improved margins and strengthened our customer relationships including the completion of an agreement with a key customer. As we look ahead, we remain focused on becoming a best-in-class U.S. tower operator by driving additional operating efficiencies, modernizing our systems, and increasing our land ownership under our towers.”
Chris Hillabrant, Crown Castle’s President and Chief Executive Officer
Criteo S.A. reported a decrease in revenue to $1.27 billion for the nine months ended September 30, 2026, compared to $1.40 billion in the prior year period. Net income for the same period significantly declined to $26.5 million from $103.0 million, driven by lower gross profits and sustained operating expenses.
Seneca Foods reported net earnings of $48.7 million for the six months ended September 26, 2026, an increase from $44.6 million in the prior year period, driven by a significant rise in net sales to $897.8 million. The company's balance sheet remains inventory-heavy at $795.9 million, while total stockholders' equity grew to $802.1 million.
For the nine months ended September 30, 2026, Manitowoc reported net sales of $1,703.3 million, an increase from $1,563.8 million in the prior year. Net income significantly improved to $19.2 million compared to $0.2 million in 2025, driven by higher gross profits and improved operating income across its global lifting products segments.
Myriad Genetics reported Q3 2026 revenue of $202.7 million and raised its full-year revenue guidance mid-point. The company also highlighted a definitive agreement to sell its Prenatal Health business to Labcorp for $210 million in cash to focus on its Cancer Care Continuum and Mental Health segments.
Counterparty
Labcorp
“We have made meaningful progress on our path to accelerate profitable growth and strengthen the company’s financial profile. Our third quarter 2026 financial results exceeded our expectations, led by our on-going focus on the Cancer Care Continuum (CCC).”
Sam Raha, President and CEO, Myriad Genetics
“The sale of our Prenatal Health business is a decisive step to support our strategic intent to increase profitable growth by focusing on the Cancer Care Continuum including screening, treatment selection and monitoring along with remission surveillance.”
Klaviyo reported Q3 2026 revenue of $387.2 million, up 25% year-over-year, and raised its full-year revenue guidance. Simultaneously, the company's board authorized a new $300 million share repurchase program following the completion of its previous $500 million program.
“AI is taking barriers out of marketing, and as agents take on more of the work, they are only as good as the context behind them. Since our founding we have placed customer relationships and data at our core, and this puts Klaviyo at the center of this shift. We provide the engine that fuels our customers’ growth: a B2C CRM that integrates data and decisioning with purpose-built agents for marketing and customer service. That's why more than 211,000 brands around the globe trust Klaviyo to turn their customer data into personalized experiences that help them grow.”
Andrew Bialecki, co-founder and co-CEO of Klaviyo
“Q3 was another strong quarter with revenue up 25% year-over-year, and solid profitability. Growth was broad-based, with strength in our largest customer cohorts demonstrating our success in the enterprise and more customers landing with multiple products from day one. We continue to drive growth with disciplined investments, and our innovation engine keeps us ahead of customer needs. I have deep conviction in the runway ahead as we scale profitably and execute our strategy to expand across multiple products, in the enterprise, and internationally, and build on the momentum with our agents.”
Permian Resources reported strong third-quarter 2026 results with total production increasing 22% quarter-over-quarter to 457.5 MBoe/d. The company generated $846 million in adjusted free cash flow and raised its full-year oil production guidance mid-point to 202.5 MBbls/d.
Term
Q3 2026
“This marks another outstanding quarter from the Permian Resources team, with continued execution across the board. During the third quarter, we responded to a strong price environment with higher production across all three commodity streams. Importantly, we were able to generate production growth while maintaining cost discipline, delivering record low total controllable cash costs per Boe.”
Will Hickey, Co-CEO of Permian Resources
“Throughout the year our team has reacted quickly to higher commodity prices, growing production in order to maximize value for shareholders. Importantly, we have been able to accomplish this through rapid payback initiatives such as increasing working interest, accelerating workover activity and reducing cycle times, while maintaining our current rig and fleet counts.”
Root, Inc. reported its Q3 2026 financial results, achieving $14 million in net income and $381 million in revenue. The company highlighted strong profitability with an 18% annualized return on equity and a 97.2% net combined ratio. Strategic updates included the renewal of its Carvana partnership through 2028 and the launch of a pilot program with Hyundai dealerships.
“In the third quarter, Root delivered another quarter of strong profitability while continuing to advance the products, technology, and distribution capabilities designed to drive our next phase of growth.”
Alexander Timm, Chief Executive Officer and Director
“We remained disciplined in Direct and deployed capital only where expected returns met our thresholds. In a cyclical insurance market, that discipline is a prerequisite for compounding value.”
Alexander Timm, Chief Executive Officer and Director
agilon health reported third quarter 2026 revenue of $1.52 billion, a 6% increase year-over-year, and a net income of $35 million compared to a net loss in the prior year. The company raised its full-year 2026 guidance for revenue and Adjusted EBITDA following stronger-than-expected performance in burden of illness and payor contracting.
“agilon’s third quarter results exceeded our expectations, reflecting the disciplined execution and operational progress our team has delivered this year. Central to that progress is our proximity to physicians and their patients, which differentiates our model and enables us to pair trusted relationships with actionable insights that help deliver better outcomes at the point of care.”
Tim O’Rourke, Chief Executive Officer of agilon health
Sturm, Ruger & Company reported Q3 2026 net sales of $147.6 million, a 16.5% increase year-over-year, and diluted EPS of $0.36. The company also announced a quarterly dividend of $0.18 per share and a strategic decision to suspend production of certain low-margin product families representing $25 million in annual revenue to improve manufacturing efficiency.
Term
Q3 2026
“Our third quarter results reflect continued operational progress. We delivered another quarter of year-over-year and sequential sales growth while also delivering year-over-year and sequential improvement in profitability.”
Todd Seyfert, President and Chief Executive Officer
“Portfolio rationalization makes Ruger stronger. We are taking a disciplined look at where we deploy our people, equipment and capital and ensuring they are focused on the products and platforms that deliver the most value to our customers and shareholders.”
Todd Seyfert, President and Chief Executive Officer
Aeva Technologies reported record third quarter 2026 revenue of $6.7 million, driven by increased volumes of its 4D LiDAR and optical solutions. The company highlighted new airborne autonomy development selections by the US Air Force and US Navy, as well as a multi-year supply agreement with Micro-Epsilon for factory automation.
Term
Q3 2026
“Aeva achieved a new record revenue in Q3, driven by record volume of our 4D LiDAR and optical solutions and the ongoing scaling of manufacturing. Our growing traction across many markets, from automotive to optical communications, reflects the unique versatility of Aeva’s core technology platform to deliver differentiated capabilities for a broad range of applications. As demand accelerates, our focus remains on executing for our customers, securing additional wins and further scaling to meet demand.”